Tag Archive for: Delsitech

DelSiTech and Tolmar Announce Global License and Development Agreement

Tolmar secures global license to DelSiTech’s Silica Matrix technology to develop and commercialize two undisclosed drug targets DelSiTech and Tolmar to expand development of additional drug products across a range of therapeutic areas DelSiTech is eligible to receive upfront payments, development and commercial milestone payments, and royalties on licensed products Turku, Finland and Dublin, Ireland […]

DelSiTech Announces Positive Topline Clinical Data From Phase 1 Trial With Its Sustained Release Eye Drop Platform

Turku, Finland – 29th June 2023: Drug delivery and development company DelSiTech today reported positive topline results from its Phase 1 clinical trial, evaluating the safety and tolerability of DST-2105, DelSiTech’s first of its kind, silica-based, long-acting demulcent eye drop product. Read more…  

DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine

Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop long-acting injectable formulations ensuring the slow release of human immunodeficiency virus (HIV) vaccine. This funding marks the third grant awarded from the Bill […]

DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company […]

DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology

Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Anticancer Bioscience Ltd., an innovative China-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology. The collaboration joins […]